{
  "slug": "takara-bio",
  "name": "Takara Bio",
  "description": "Takara Bio is a leading Japanese biotechnology company focused on developing, manufacturing, and selling reagents and instruments for life science research. They also provide services and products related to gene therapy and cell therapy, including contract development and manufacturing organization (CDMO) services for novel gene and cell therapy products.",
  "url": "https://optimly.ai/brand/takara-bio",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://takarabio.org/",
  "baiScore": 41,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-07-26T00:02:23.105Z",
  "verifiedVitals": {
    "website": "www.takarabio.com",
    "founded": "1979",
    "headquarters": "Shiga, Japan",
    "pricing_model": "Product sales (reagents, kits, instruments), service contracts (CDMO, custom services), licensing agreements.",
    "core_products": "PCR reagents, reverse transcriptase, gene editing tools, stem cell research tools, cell culture media, gene and cell therapy CDMO services.",
    "key_differentiator": "Strong brand reputation for quality and reliability in molecular biology tools, significant expertise and growing capacity in gene/cell therapy manufacturing, and a comprehensive portfolio spanning research to clinical application.",
    "target_markets": "Academic research institutions, pharmaceutical companies, biotechnology firms, clinical research organizations.",
    "employee_count": "Approximately 1,600 (as of recent reports, includes global subsidiaries)",
    "funding_stage": "Publicly traded (part of Takara Holdings, traded on Tokyo Stock Exchange)",
    "subcategory": "Life Science Research & Gene Therapy"
  },
  "intentTags": {
    "problemIntents": [
      "In-house lab development: Instead of buying specialized kits, labs could develop and optimize their own reagents or protocols from basic chemicals, though this is often more time-consuming and less re",
      "Contract Research Organizations (CROs): For complex research or therapy development, companies might engage full-service CROs instead of just procuring reagents or CDMO services, relying on the CRO fo",
      "Delaying or Abandoning Projects: Without access to reliable tools or manufacturing capabilities, certain research or therapeutic development projects might be delayed indefinitely or abandoned due to "
    ],
    "solutionIntents": [
      "Takara Bio products",
      "Takara Bio gene therapy CDMO",
      "Takara Bio PCR reagents",
      "Takara Bio careers",
      "Who owns Takara Bio",
      "Other Reagent Suppliers: Researchers could opt for PCR kits, enzymes, or cell culture media from competing brands like New England Biolabs, Promega, or Sigma-Aldrich."
    ],
    "evaluationIntents": []
  },
  "timestamp": 1785234839047
}